About Obio
  Corporate Overview
  Obio Management & Structure
  Management Team
    Board of Directors
Technical Board
  Shareholders Structure
 
 
 
 
 
Board of Directors

Francis CHI Eddie Kin Man CHAN
Dr. Bill Piu CHAN Abraham Yu Ling CHAN
Kin Chung CHENG Hyun Oh CHO
Dr. Royston Frederick DRUCKER Yong Chian TAN
Dr. Jess Thoene Frankie Yuet Leung WONG

Francis CHI, BA (Fin.), Founder and Chairman top
Founder of Obio who plays a leading role in developing the Company's direction in pursuit of its business and operational objectives. Mr. Chi is responsible for the business development and the commercial activities of the Company, including the manufacturing and marketing of all product applications. He holds a Bachelor of Arts degree in Business Administration from the University of Seattle, U.S.A. Mr. Chi has over 25 years of entrepreneurial experience, of which he has spent 19 years in the fields of organic and inorganic chemicals, fertilizers, pharmaceuticals, bio-chemicals and animal feeds.

Eddie Kin Man CHAN, CPA top
Practising accountant and a graduate of the Hong Kong Polytechnic University. In 1989, Mr Chan founded Chan, Wong, Chung & Co. (now CWCC), a certified public accountants firm. He is a Fellow of the Association of Chartered Certified Accountants and a Fellow of the Hong Kong Institute of Certified Public Accountants. Because of his enriched knowledge and experience in accounting as well as his high reputation in the industry, he has been Vice-President of the China Tax Society since 1991 and contributing the development of China taxation system.

Dr. Bill Piu CHAN, MD, CTO top
Dr. Chan is currently Professor and Director of the Beijing Institute of Geriatrics and a member of American Academy of Neurology. He has been appointed as the Deputy Director and Principal Investigator of Chinese National Human Genome Center Beijing since 2001. He is the Vice President of the Chinese Society of Gerontology and Geriatrics, council member of the International Association of Gerontology and Geriatrics (IAGG), and Secretary of the IAGG Asia-Oceania Region. He was the President of the Society of Chinese Neuroscientists in America from 1998 to 2000 and the Secretary of Asia-Pacific Society for Neurochemistry from 2000 to 2006. In 2002, he attained First Award for Scientific Achievement from both Ministry of Education and Chinese Medical Association in China.

Dr. Chan graduated from Human Medical College in Changsha and became a neurologist after the fellowship training. He later acquired his PhD on neurosciences from Sun Yan-Sen University of Medical Sciences in Guangzhou followed by postdoctoral training at the Parkinson's Institute in Sunnyvale, California of USA where he spent more than 10 years as senior scientist before returned back to China.  Dr. Chan is well known for his clinical and basic research on Parkinson’s disease and geriatric disorders. 


Abraham Yu Ling CHAN, BASc, C.Eng., MIStruct E., P.Eng. top
Mr Chan received his bachelor’s degree of Applied Science from University of Toronto and attained qualification of Chartered Engineer in U.K.. Presently the Chairman and Chief Executive Officer of PuraPharm Corporation, a branded Chinese Medicine company based in Hong Kong. Mr. Chan has a strong dedication to community services. He was Advisory Committee Chairman of School of Chinese Medicine, Hong Kong Baptist University and Member of Commission on Strategic Development, The Government of HKSAR. Now he is a part-time member of Central Policy Unit, HKSAR, Director of Hong Kong Jockey Club Institute of Chinese Medicine Limited, Director & President of Modernized Chinese Medicine International Association (MCMIA), International Society of Oriental Medicine’s Director (Hong Kong Representative), Council Member of the Hong Kong Health Food Association and Association of Hong Kong & Kowloon Practitioners of Chinese Medicine’s Affair Advisor.

Kin Chung CHENG, MPA, CPA, CFO top
He is also currently the Executive Director and Chief Executive Officer of Poly Genius Consulting Limited, a firm specializing governance, risk and compliance management. Mr. Cheng graduated from The Hong Kong Polytechnic University with a Master degree in Professional Accounting. Prior to joining the Group, Mr. Cheng was the Chief Financial Officer and subsequently the Chief Information and Investment Officer of a listed electronic group in Hong Kong and a Partner at Deloitte Touche Tohmatsu and also acted as a Business Development Director of the Corporate Finance arm of the same firm.

Hyun Oh CHO, MBM top
Mr. Cho is an expert in finance and investment area. He holds degree of BA from Korea University and MBM from Asian Institute of Management. He has working experience of two years in Export Import Bank of Korea, nine years in Citibank Treasury as Vice President in Seoul and Tokyo, and three years as director in Salomon Brothers Securities Arbitrage Team in Tokyo and Hong Kong. He has run a hedge fund, Simplex Capital, based in Tokyo and Hong Kong for six years until 2006.

Dr. Royston Frederick DRUCKER, MD top
Dr. Drucker obtained a physician qualification from Cambridge University. He is a founder and honorary member of the Association for Human Pharmacology in the Pharmaceutical Industry, a fellow of the Royal Society of Medicine, and a member of the Securities Institute. After a career of 8 years in clinical practice, he joined the research and development division of Sterling-Winthrop Limited as senior departmental manager of the Department of Biochemistry. Later he was appointed European Head of clinical pharmacology, Executive Director and subsequently Corporate Vice President of drug development at the Upjohn Company in the U.S. From 1996 to 2005, he was General Manager of Technomark Consulting Services Limited. He is now the Medical Director of e-Therapeutics, responsible for organizing and supervising clinical trials for drug candidates of the company. He also serves in the Technical Board of Obio.

Yong Chian TAN, BSc (Eng) top
Holds a Bachelor of Science degree in Civil Engineering from the University of Seattle, U.S.A . Prior to joining the Company in 2001, he worked for the Walsin Lihwa Group, which is listed in Taiwan and has diverse operations covering power, telecommunications, cable and wire, steel, electronic components and semiconductors. His latest roles in the Walsin Lihwa Group were as President of HannHann Corporation and DongGuang Hannstar Electronics Company Limited, where he was responsible for establishing operations in China. He has over 10 years senior experience in project management, and the operations and management of new businesses in China and Taiwan.

Dr. Jess THOENE, MD top
Dr. Thoene attended his undergraduate program majoring in Chemistry at Stanford University and furthered his studies at the medical school of Johns Hopkins University. His pediatric residency was in the Harriet Lane Home Pediatric program. He also completed a 3-year fellowship in metabolic genetic disease at the University of California, San Diego. Dr. Thoene is a member of the American Society of Clinical Investigation and the American Pediatrics Society. From 1988-89, he served as the Chairman of the National Commission of Orphan Diseases and the Chairman of the Board of the National Organization for Rare Disorders. From 2000-2006 he served as the Karen Gore Professor of Pediatrics, Director of the Hayward Genetics Center and Human Genetics Program at Tulane University Health Sciences Center. He is currently Active Professor Emeritus at the University of Michigan In the Division of Pediatric Genetics.

Frankie Yuet Leung WONG, BA, BSc (Econ) top
Holds a Master of Arts degree from the University of Lancaster and a Bachelor of Science degree in Economics from the London School of Economics and Political Science. Mr Wong joined the Shui On Group of Companies in 1981 and is the Managing Director of Shui On Holdings Limited, a position he has held since 1991. He is also the Chief Executive Officer of Shui On Construction and Materials Limited, a company listed on the Hong Kong Stock Exchange. Prior to his service at Shui On, he worked for various major international banks in Hong Kong.